Biogen

Youtube Subscribe

Open: 225.45 Close: 223.24 Change: -2.21

Are you still looking for information about Biogen Stock? An AI summarized it for you.

The game is changing. There is a new strategy to evaluate Biogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, Leqembi, year, CEO, say, Biogens, Support, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

21 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. Donanemab, if approved, would follow Eisais Leqembi, which was approved last year, and Biogens Aduhem. Biogen missed Wall Street estimates for fourth-quarter profit.

Today's News

Biogen bought Reata Pharmaceuticals for $7.3 billion last year. CEO Chris Viehbacher says neuroscience is no longer forgotten therapeutic area of the late 2010s. 21 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Biogens market position. Biogen Support Services 1-800-456-2255 (U.S. residents only) Multiple Sclerosis Support Services. SMA Support SMA360°™ 1-844-477-4672. Department of Justice seeking information about Biogens business operations in several foreign countries On this news, Biogen stock price fell $5.91 per share, or 2.6%, to close at $220.74 per share on February 14, 2024. Donanemab, if approved, would follow Eisais Leqembi, which was approved last year, and Biogens Aduhelm. Biogen announced earlier this year that it would stop selling Aduhem. Biogen discontinued it in January. Eisai CEO Haruo Naito says launch of newly-approved Alzheimers drug Leqembi has been slower than expected in the U.S. Biogen relying on success of leqemba following discontinuation of aduhelm. Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls. CEO sees progress of launch of Leqembi drug. China approves Alzheimers treatment by Eisai and Biogen. Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (Biogen) Such investors are advised to contact Glancy Prongay & Murray LLP, a leading Securities Fraud Law Firm, on Behalf of Investors. Biogen (BIIB, $216.9) RSI Indicator left the oversold zone on February 29, 2024. Biogen missed Wall Street estimates for fourth-quarter profit on Tuesday. The biotechnology company says it will record a one-time charge of about $60 million related to close-out costs. The results come amid the rollout of Biogen and Eisais Leqembi. Biogen discovers, develops and delivers innovative therapies worldwide for people living with neurological and neurodegenerative diseases. Biogen also manufactures and commercializes biosimilars of advanced biologics. Biogen stock (nasdaq:biib), quotes and news summary - benzinga.org. Biogen is in the Health Care sector and Biotechnology industry. The latest price target for Biogen (NASDAQ : BIIB ) was reported by RBC Capital on March 5, 2024.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

Are looking for the most relevant information about Biogen? Investor spend a lot of time searching for information to make investment decisions in Biogen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, Leqembi, year, CEO, say, Biogens, Support, and the most common words in the summary are: biogen, job, stock, best, alzheimers, report, inc, . One of the sentences in the summary was: Biogen missed Wall Street estimates for fourth-quarter profit.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #job #stock #best #alzheimers #report #inc.

Read more →

Youtube Subscribe

---